Mr Mrs Miss Ms Dr Other

Dr
Robert
Scanes

Patent Attorney

London Office

Chemistry

Telephone. +44(0) 207 776 5100
Email. rscanes@hgf.com
Vcard

Experience

Robert specialises in patents and related IP rights in the fields of chemistry, pharmaceuticals and biotechnology.

He has broad experience in patent practice, including urgent drafting for SARS-CoV-2 antivirals during the COVID-19 pandemic, coordinating global patent portfolios for a pharmaceutical candidate in phase III clinical trials and contentious proceedings before the European Patent Office defending market exclusivity determining patents for authorised drugs. Robert also provides advice regarding freedom-to-operate and validity.

He is familiar with the differing needs of prosecuting applications in several fields, encompassing consumer goods, graphene technology and polymer chemistry.

Robert's technical experience spans the interface between chemistry and biology, working on new chemical entity, polymorphic form, dosage regimen and subsequent medical use cases.

Before joining the profession Robert discovered a new oscillating chemical reaction during his doctoral research, work that was highlighted in the journal Science. His laboratory work reflected his long-held interests in enantioselective catalysis, non-linear reaction kinetics, protocell movement, oligonucleotide modification and super-resolution microscopy. He holds a first class Master's degree in Natural Sciences from the University of Cambridge, where he was awarded scholarships and bursaries for academic performance.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

BA

BA in Natural Sciences, First Class, University of Cambridge

MSCI

Natural Sciences, First Class, University of Cambridge

POSTGRADUATE DIPLOMA OR CERTIFICATE

Intellectual Property Law, Distinction, Queen Mary University of London

OTHER

DPhil in Organic Chemistry, Thesis Title "Selection among Replicators and Protocell Chemotaxis", University of Oxford

Publications

UPC delivers first judgment on Validity and Infringement of a Second Medical Use Claim

View publication online

T 0295/22: Apremilast decision highlights hopes and challenges for broad second medical use claims

View publication online

T 1418/22: Acalabrutinib provides guidance on establishing inventiveness of polymorphs at the EPO

View publication online

Related News

Event - 18th November 2026

HGF Venture: Funding the Future

Join fellow life sciences founders, investors and business leaders for an evening of drinks and networking in Cambridge on the 18th November, 5-9pm. Featuring an investor-founder round table and an …

Event details
Event - 22nd September 2026

HGF are sponsors of LSPN Europe 2026

HGF is proud to sponsor LSPN Europe 2026, the premier event for IP professionals in the life sciences sector. Join us on September 22-23 in Basel for two days packed …

Event details
Event - 2nd September 2026

IP Clinic for SMEs at ETZ EnergyWorks

If you’re developing a new technology or growing your business, understanding your intellectual property (IP) early can help you protect your innovation, attract investment and avoid costly mistakes. Join HGF …

Event details
Event - 16th September 2026

Basel seminar - New developments in SPCs

VENUE – Der Teufelhof Basel, The Archaeological Cellar Join us on Wednesday 16th September 5:30 – 8:00 pm (CEST) for our seminar on the latest developments in Supplementary Protection Certificates …

Event details
Event - 10th July 2026

IP Clinic for SMEs at ETZ EnergyWorks

If you’re developing a new technology or growing your business, understanding your intellectual property (IP) early can help you protect your innovation, attract investment and avoid costly mistakes. Join HGF …

Event details
Event - 24th June 2026

IP Clinic for SMEs at ETZ EnergyWorks

Following the success of our first session, we’re pleased to announce our next Intellectual Property (IP) clinic taking place at ETZ EnergyWorks in Aberdeen on Wednesday 24 June 2026, from …

Event details
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us